Boron neutron capture therapy for undifferentiated thyroid carcinoma: Preliminary results with the combined use of BPA and BOPP

Applied Radiation and Isotopes

Volumn 61, Issue 5, 2004, Pages 905-909

  Viaggi, M ^a   Dagrosa, M A ^a   Longhino, J ^b   Blaumann, H ^b   Calzetta, O ^b   Kahl, S B ^c   Juvenal, G J ^a   Pisarev, M A ^a,d  

^a Av del Libertador 8250 1429   (Argentina)

^b CENTRO ATÓMICO BARILOCHE   (Argentina)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

ARO; BNCT; BOPP; BPA; Cancer; Thyroid

Indexed keywords

BORON COMPOUNDS; CARCINOGENS; CELLS; ELECTROMAGNETIC WAVES; RADIOISOTOPES;

BIODISTRIBUTIONS; BORON NEUTRON CAPTURE THERAPY (BNCT); UNDIFFERENTIATED HUMAN THYROID CANCER (UTC);

NEUTRON BEAMS;

2,4 BIS(DIHYDROXYETHYL)DEUTEROPORPHYRIN IX TETRAKIS CARBORANE CARBOXYLATE ESTER; 4 BORONOPHENYLALANINE; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CELL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; MOUSE; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH; UNDIFFERENTIATED CARCINOMA;

ANIMALS; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; CELL LINE, TUMOR; DEUTEROPORPHYRINS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHENYLALANINE; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 4143087174     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2004.05.005     Document Type: Conference Paper

References (11)

1. Ain K.B. Anaplastic thyroid carcinoma. behavior, biology, and therapeutic approaches Thyroid. 8:1998;715-726
2. Attix F.H. Introduction to Radiological Physics and Radiation Dosimetry. 1986;Wiley, New York
3. Calzetta Larrieu O., Blaumann H., Longhino J. RA-6 reactor mixed beam design and performance for NCT trials. Sauerwein W., Moss R., Witting A. Research and Development in Neutron Capture Therapy. 2002;155-158 Monduzzi Editore, Essen, Germany
4. Ceberg C., Brun A., Kahl S., Koo M.S., Person B., Salford L.G.A. Comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J. Neurosurg. 83:1995;86-92
5. Coderre J.A., Morris G. The radiation biology of boron neutron capture. Radiat. Res. 151:1999;1-18
6. Dagrosa M.A., Viaggi M.E., Kreimann E., Farias S., Garavaglia R., Agote M., Cabrini R.L., Dadino J.L., Juvenal G., Pisarev M. Selective uptake of p-borophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy. Thyroid. 12:2002;7-12
7. Dagrosa M.A., Viaggi M., Longhino J., Calzetta O., Cabrini R., Edreira M., Juvenal G., Pisarev M. Experimental application of boron neutron capture therapy (BNCT) to undifferentiated thyroid carcinoma (UTC). Int. J. Radiat. Oncol. Biol. Phys. 57:2003;1084-1092
8. Hill J., Kahl S.B., Kaye A., Stylli S.S., Koo M.S., Gonzales M., Vardaxis N.J., Johnson C. Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc. Natl. Acad. Sci. USA. 89:1992;1785-1789
9. Lee Y.-S., Bulliard D.E., Zalutsky M.R. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131 I - radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res. 48:1988;559-565
10. Tibbitts J., Sambol N.C., Fike J.R., Bauer W., Kahl S.B. Plasma pharmacokinetics and tissue biodistribution of boron following administration of a boronated porphyrin in dogs. J. Pharm. Sci. 89:2000;469-477
11. Viaggi M., Dagrosa M.A., Gangitano D., Belli C., Larripa I., Cabrini R., Pisarev M., Juvenal G. Description of a new undifferentiated carcinoma model in a nude mice. Thyroid. 13:2003;529-536